About this item:

205 Views | 160 Downloads

Author Notes:

Corresponding author: Alvaro Alonso, MD, PhD. Department of Epidemiology, Rollins School of Public Health, Emory University. 1518 Clifton Rd NE, CNR Room 3051, Atlanta, GA 30322. Phone: +1 404 727 8714. alvaro.alonso@emory.edu

Alvaro Alonso had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Dr. Bengtson is an employee of Optum.

All other authors have no disclosures.

Subjects:

Research Funding:

This work was supported by grant R01-HL122200 from the National, Heart, Lung and Blood Institute and American Heart Association grant 16EIA26410001 (Alonso).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Cardiovascular System & Cardiology
  • ACUTE HEPATITIS
  • WARFARIN
  • DABIGATRAN
  • HEPATOTOXICITY
  • METAANALYSIS
  • RIVAROXABAN
  • APIXABAN
  • SAFETY
  • CODES

Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation

Tools:

Journal Title:

Heart

Volume:

Volume 103, Number 11

Publisher:

, Pages 834-839

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Objective: To assess the risk of liver injury hospitalisation in patients with atrial fibrillation (AF) after initiation of direct oral anticoagulants (DOACs) or warfarin and to determine predictors of liver injury hospitalisation in this population. Methods: We studied 113 717 patients (mean age 70, 39% women) with AF included in the MarketScan Commercial and Medicare Supplemental databases with a first prescription for oral anticoagulation after 4 November 2011, followed through 31 December 2014. Of these, 56 879 initiated warfarin, 17 286 initiated dabigatran, 30 347 initiated rivaroxaban and 9205 initiated apixaban. Liver injury hospitalisation and comorbidities were identified from healthcare claims. Results: During a median follow-up of 12 months, 960 hospitalisations with liver injury were identified. Rates of liver injury hospitalisation ( per 1000 person-years) by oral anticoagulant were 9.0 (warfarin), 4.0 (dabigatran), 6.6 (rivaroxaban) and 5.6 (apixaban). After multivariable adjustment, liver injury hospitalisation rates were lower in initiators of DOACs compared with warfarin: HR (95% CI) of 0.57 (0.46 to 0.71), 0.88 (0.75 to 1.03) and 0.70 (0.50 to 0.97) for initiators of dabigatran, rivaroxaban, and apixaban, respectively (vs. warfarin). Compared with dabigatran initiators, rivaroxaban initiators had a 56% increased risk of liver injury hospitalisation (HR 1.56, 95% CI 1.22 to 1.99). In addition to type of anticoagulant, prior liver, gallbladder and kidney disease, cancer, anaemia, heart failure and alcoholism significantly predicted liver injury hospitalisation. A predictive model including these variables had adequate discriminative ability (C-statistic 0.67, 95% CI 0.64 to 0.70). Conclusions: Among patients with non-valvular AF, DOACs were associated with lower risk of liver injury hospitalisation compared with warfarin, with dabigatran showing the lowest risk.

Copyright information:

© 2017, BMJ Publishing Group. All rights reserved.

Export to EndNote